Biotech News

Medical Technology Breaking News: Aethlon Medical (OTCBB: AEMD) Announces First Patient Completes Hemopurifier Clinical Study Protocol SAN DIEGO - February 26, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), the pioneer in developing targeted therapeutic devices to address infectious diseases and cancer, today announced that the first patient enrolled in the Company's FDA approved feasibility study has completed their full Hemopurifier treatment protocol without any device-related adverse events.

Cellceutix Corp. (CTIX) is "One to Watch" February 25, 2015 (www.investorideas.com newswire) Clinical-stage biopharma company Cellceutix has been getting a lot of attention lately, thanks in large part to their milestone successes developing what is arguably a world-class drug portfolio pipeline.

VistaGen Therapeutics, Inc. (VSTA) Working to Revolutionize Depression Treatment February 24, 2015 (www.investorideas.com newswire) Ketamine has been shown as an extremely effective treatment for patients suffering from major depressive disorder (MDD).

Medical Technology Breaking News: Aethlon Medical, Inc. (OTCBB: AEMD) - CTE Data Presentation at the Upcoming 2015 TBI Conference SAN DIEGO - February 24, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD), today published an article on The Chairman's Blog, written by the Company's Chairman and CEO, Jim Joyce.

PlasmaTech Biopharmaceuticals, Inc. (PTBI) Leverages Platforms to Drive Growth February 23, 2015 (www.investorideas.com newswire) PlasmaTech Biopharmaceuticals is focused on advancing targeted treatments for the unmet needs of critical patient care through the use of two proprietary platforms, Salt Diafiltration Process (SDP) and Polymer Hydrogel Technology (PHT).

Immuno-Oncology Promises Continued Wealth and Health: LifeTech Capital's Stephen Dunn February 20, 2015 (www.investorideas.com newswire) Immuno-oncology -- disabling cancer's defenses so that a patient's own immune system can seek it out and destroy it--took center stage in the drug development world in 2014.

VistaGen Therapeutics, Inc. (VSTA) Partners with NIH in its Sponsored Phase 2 Study of Orally-Active AV-101 in MDD February 17, 2015 (www.investorideas.com newswire) VistaGen Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative medicine for depression and conditions associated with the central nervous system, has entered into a Cooperative Research and Development Agreement (CRADA) with the U.S. National Institute of Mental Health (NIMH), a component of the U.S. National Institutes of Health (NIH).

Medical Technology Breaking News: Aethlon Medical, Inc. (OTCBB: AEMD) - "A Publication Describing the First Treatment of Ebola with the Aethlon Hemopurifier(R)" New York, NY - February 13, 2015 (Investorideas.com newswire) Aethlon Medical, Inc. (OTCBB:AEMD) today published a new blog post on The Chairman's Blog, written by the Company's Chairman and CEO, James Joyce.

Medical Technology Breaking News: SeeThruEquity Issues Quarterly Update Note on Aethlon Medical, Inc. (OTCBB: AEMD) New York, NY - February 13, 2015 (Investorideas.com newswire) SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued a quarterly update note on Aethlon Medical, Inc. (OTCBB:AEMD).

Follow the Money with Investorideas.com; Biotech Stocks Point Roberts, WA - NEW YORK, NY - February 11, 2015 (www.investorideas.com newswire) Investorideas.com, a global news source covering leading sectors including biotech, medical technology and life sciences stocks updates its biotech stocks directory for investors following the sector.

Subscribe to Biotech News RSS

Biotech News from Marketwired

InvestorIdeas-Biotech 

• Esperion Therapeutics to Provide Fourth Quarter and Full Year ETC-1002 Program Updates and Financial Results (Thu, 26 Feb 2015 21:30:00 GMT)  Esperion Therapeutics to Provide Fourth Quarter and Full Year ETC-1002 Program Updates and Financial Results
• Bio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results (Thu, 26 Feb 2015 21:15:00 GMT)  Bio-Rad Reports Fourth-Quarter and Full-Year 2014 Financial Results
• Pegasystems Announces Financial Results for Fourth Quarter and Fiscal Year 2014 (Thu, 26 Feb 2015 21:02:00 GMT)  Pegasystems Announces Financial Results for Fourth Quarter and Fiscal Year 2014

Subscribe to Biotech News

Stock Quotes

Biotech/ Pharma Stock Directory

Our biotech stocks directory includes Stem Cell Stocks, Medical Stocks, Life Sciences, Therapeutics and Pharma Stocks . Our Directory includes publicly traded biotech stocks on the TSX, TSX Venture, OTC, NASDAQ, AMEX, NYSE, ASX, AIM and other leading Stock Exchanges.

Preview

Aastrom Biosciences, Inc. ( NasdaqCM: ASTM ) is the leader in developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. Aastrom markets two autologous cell therapy products in the United States for the treatment of cartilage repair and skin replacement. Aastrom is also developing MACI(TM), a third-generation autologous chondrocyte implant for the treatment of cartilage defects in the knee, and ixmyelocel-T, a patient-specific multicellular therapy for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy.

ABBOTT LABORATORIES ( NYSE: ABT ) is a global healthcare company devoted to improving life through the development of products and technologies that span the breadth of healthcare. With a portfolio of leading, science-based offerings in diagnostics, medical devices, nutritionals and branded generic pharmaceuticals, Abbott serves people in more than 150 countries and employs approximately 69,000 people.

Ablynx ( Brussels: ABLX.BR ) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and pulmonary disease.

Acadia Pharmaceuticals Inc. ( NasdaqGS: ACAD ) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in neurological and related central nervous system disorders. ACADIA has a pipeline of product candidates led by pimavanserin, for which we have reported positive Phase III trial results in Parkinson's disease psychosis and which has the potential to be the first drug approved in the United States for this disorder. We are currently completing NDA-enabling clinical and manufacturing activities for pimavanserin and are planning to submit an NDA with the FDA near the end of 2014. Pimavanserin is also in Phase II development for Alzheimer's disease psychosis and has successfully completed a Phase II trial in schizophrenia. ACADIA also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two preclinical programs directed at Parkinson's disease and other neurological disorders. All product candidates are small molecules that emanate from internal discoveries.

Access Pharmaceuticals, Inc. ( OTC:ACCP ) is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access developed MuGard and ProctiGard and is developing multiple follow-on products. Access also has other advanced drug delivery technologies including CobaCyte™-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology based on the natural vitamin B12 uptake mechanism.

Acorda Therapeutics, Inc. ( NasdaqGS:ACOR ) is a biotechnology company focused on developing therapies that improve the lives of people with neurological disorders. Acorda markets three FDA-approved therapies including: AMPYRA (dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve walking in patients with multiple sclerosis (MS); ZANAFLEX CAPSULES® (tizanidine hydrochloride) and Zanaflex tablets, a short-acting drug for the management of spasticity; and QUTENZA® (capsaicin) 8% Patch, for the management of neuropathic pain associated with postherpetic neuralgia. AMPYRA is marketed outside the United States as FAMPYRA® (prolonged-release fampridine tablets) by Biogen Idec under a licensing agreement from Acorda. Acorda has one of the leading pipelines in the industry of novel neurological therapies. The Company is currently developing six clinical-stage therapies and one preclinical stage therapy that address a range of disorders including post-stroke deficits, epilepsy, stroke, peripheral nerve damage, spinal cord injury, neuropathic pain, and heart failure.

See the full biotech stocks directory and login as a member or access as a PDF

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

SPDR S&P BIOTECH ETF ( NYSEArca: XBI ) The investment seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of an index derived from the biotechnology segment of a U.S. total market composite index. In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology industry group of the S&P Total Market Index ("S&P TMI"). The fund is non-diversified.